Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML)

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 1, 2008, Pages 85-92

  Appelbaum, Frederick R ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

acute myeloid leukemia; chemotherapy; hematopoietic cell transplantation; minimal residual disease; multicolor flow cytometry; PCR based assays

Indexed keywords

ANTILEUKEMIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD DONOR; CANCER SURVIVAL; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOGENETICS; DISEASE FREE SURVIVAL; DONOR SELECTION; EVIDENCE BASED MEDICINE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NEOPLASM, RESIDUAL; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 40749159081     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.11.013     Document Type: Review

References (19)

1. Davies SM, Rowe JM, Appelbaum FR. Indications for hematopoietic cell transplantation in acute leukemia. Biol Blood Marrow Transplant, in press.
2. Yanada M., Matsuo K., Emi N., et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 103 (2005) 1652-1658
3. Schlenk R.F., Corbacioglu A., Krauter J., et al. Gene mutations as predictive markers for postremission therapy in younger adults with normal karyotype AML. Blood 108 (2006) 6a [abstract 4]
4. Levi I., Grotto I., Yerushalmi R., et al. Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leukemia Research 28 (2004) 605-612
5. Krauter J., Heil G., Hoelzer D., et al. Role of consolidation therapy in the treatment of patients up to 60 years with high risk AML. Blood 106 (2005) 54a [abstract 172]
6. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. The New England Journal of Medicine 351 (2004) 2276-2285
7. Center for International Blood and Marrow Transplant Research. Available from: (2007). www.cibmtr.org [accessed 9.05.07]. Ref Type: Electronic Citation
8. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. Journal of Clinical Oncology 10 (1992) 1723-1729
9. Brown R.A., Wolff S.N., Fay J.W., et al. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group. Blood 85 (1995) 1391-1395
10. Schiffman K., Clift R., Appelbaum F.R., et al. Consequences of cryopreserving first remission autologous marrow for use after relapse in patients with acute myeloid leukemia. Bone Marrow Transplantation 11 (1993) 227-232
11. Rowe J.M., Li X., Cassileth P.A., et al. Very poor survival of patients with AML who relapse after achieving a first complete remission: the Eastern Cooperative Oncology Group Experience. Blood 106 (2005) 162a [abstract 546]
12. Gallagher R.E., Yeap B.Y., Bi W., et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 101 (2003) 2521-2528
13. San Miguel J.F., Vidriales M.B., Lopez-Berges C., et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98 (2001) 1746-1751
14. Coustan-Smith E., Ribeiro R.C., Rubnitz J.E., et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. British Journal of Haematology 123 (2003) 243-252
15. Feller N., van der Pol M.A., van S.A., et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18 (2004) 1380-1390
16. Venditti A., Buccisano F., Del P.G., et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96 (2000) 3948-3952
17. Buccisano F., Maurillo L., Gattei V., et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 20 (2006) 1783-1789
18. Sievers E.L., Lange B.J., Alonzo T.A., et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 101 (2003) 3398-3406
19. Wood B. 9-color and 10-color flow cytometry in the clinical laboratory. Archives of Pathology & Laboratory Medicine 130 (2006) 680-690